KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
-
Stocks, gold rise as investors weigh AI boom, political turmoil
-
Swiatek coasts through Wuhan debut while heat wilts players
-
Denmark's Rune calls for heat rule at Shanghai Masters
-
Japanese football official sentenced for viewing child sexual abuse images
-
Stocks, gold steady amid political upheaval
-
'Veggie burgers' face grilling in EU parliament
-
Trio wins physics Nobel for quantum mechanical tunnelling
-
Two years after Hamas attack, Israelis mourn at Nova massacre site
-
German factory orders drop in new blow to Merz
-
Man City star Stones considered retiring after injury woes
-
Kane could extend Bayern stay as interest in Premier League cools
-
Renewables overtake coal but growth slows: reports
-
OpenAI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Extreme rains hit India's premier Darjeeling tea estates
-
Raducanu retires from opening match in Wuhan heat with dizziness
-
UK's Starmer condemns pro-Palestinian protests on Oct 7 anniversary
-
Tokyo stocks hit new record as markets extend global rally
-
Japan's Takaichi eyes expanding coalition, reports say
-
Canadian PM to visit White House to talk tariffs
-
Indonesia school collapse toll hits 67 as search ends
-
Dodgers hold off Phillies, Brewers on the brink
-
Lawrence sparks Jaguars over Chiefs in NFL thriller
-
EU channels Trump with tariffs to shield steel sector
-
Labuschagne out as Renshaw returns to Australia squad for India ODIs
-
Open AI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Tokyo stocks hit new record as Asian markets extend global rally
-
Computer advances and 'invisibility cloak' vie for physics Nobel
-
Nobel literature buzz tips Swiss postmodernist, Australians for prize
-
Dodgers hold off Phillies to win MLB playoff thriller
-
China exiles in Thailand lose hope, fearing Beijing's long reach
-
Israel marks October 7 anniversary as talks held to end Gaza war
-
Indians lead drop in US university visas
-
Colombia's armed groups 'expanding,' warns watchdog
-
Shhhh! California bans noisy TV commercials
-
New to The Street Client Partner Roadzen's DrivebuddyAI Secures EU General Safety Regulation 2144 Compliance
-
Jericho Energy Ventures and Smartkem Sign Letter of Intent to Create U.S.-Owned, Nasdaq-Listed AI-Focused Infrastructure Company
-
Medical Care Technologies (OTC Pink:MDCE) Outlines Regulatory Roadmap: Dividing AI Health Platform Into Clinical and Consumer Divisions
-
Lithium Corporation Clarifies Corporate Identity Following Rare Earths Exploration Milestone
-
SMX Brings Compliance Into High-Fashion Through Game-Changing CETI Collaboration (NASDAQ:SMX)
-
Art's Way Reports Improved Results With Modular Buildings Growth Offsetting Ag Market Challenges
-
Konica Minolta Unleashes Comic Book Magic at PRINTING United Expo
-
Inovatec to Showcase Industry-Leading Funding Automation Technology at Auto Finance Summit 2025
-
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
-
American Resources Corporation's ReElement Technologies Advances as Finalist for National Science Foundation Award as Part of the Critical Materials Crossroads Consortium
-
Green Rain Energy Holdings Inc. (OTCID:$GREH) Integrates EV Infrastructure at 8757 Rio San Diego Drive with Major SDG&E Utility Upgrade
-
New to The Street Announces 12-Month National Media Partnership with Stardust Power (NASDAQ: SDST)
-
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
-
Leeward Group Expands Offering with Launch of Leeward Trust
-
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
-
Angkor Resources Completes First Onshore Seismic Program in Cambodia; Vanderbilt Report Publishes Coverage
NYSE - LSE
| RIO | -0.34% | 66.75 | $ | |
| GSK | -0.38% | 43.285 | $ | |
| SCS | -0.06% | 16.97 | $ | |
| NGG | -0.43% | 73.58 | $ | |
| CMSC | 0% | 23.8 | $ | |
| VOD | -0.31% | 11.255 | $ | |
| RBGPF | 0% | 78.22 | $ | |
| AZN | 0.44% | 85.865 | $ | |
| BCE | -0.43% | 23.085 | $ | |
| RYCEF | -2.15% | 15.37 | $ | |
| BP | -0.54% | 34.662 | $ | |
| CMSD | -0.29% | 24.37 | $ | |
| JRI | 0.04% | 14.186 | $ | |
| BCC | 1.2% | 76.09 | $ | |
| RELX | -2.41% | 45.32 | $ | |
| BTI | 0.88% | 51.635 | $ |
KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations
Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK's clinical strategy
PROVIDENCE, RI / ACCESS Newswire / August 13, 2025 / KIFFIK Biomedical, Inc. ("Kiffik"), a leader in interstitial fluid (ISF)-based diagnostics, today announced two new appointments to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr. Reginald(Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).
"The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth," said George Cagna, CEO of KIFFIK Biomedical. "Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients."
As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.
Dr. Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for KIFFIK Dr. Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, KIFFIK and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.
About KIFFIK Biomedical
KIFFIK Biomedical is pioneering interstitial fluid (ISF)-based diagnostics, transforming disease detection and health monitoring with a needle-free, real-time approach. As a leader in ISF science and biomarker detection, we are redefining non-invasive diagnostics for oncology, therapeutic monitoring, and beyond.
Our proprietary and patented KIFFIK EXP platform unlocks the potential of ISF, providing high-precision, accessible, and patient-friendly solutions. Through strategic partnerships and cutting-edge research, KIFFIK is driving the future of precision medicine and advancing diagnostics that empower earlier detection and better health outcomes.
###
Media Contact
MDL Strategic Communications
Michael Lauer
[email protected]
SOURCE: Kiffik
View the original press release on ACCESS Newswire
P.Martin--AMWN